You are here:

NICE
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

Technology appraisal guidance
Reference number: TA193
Published: 28 July 2010

Guidance
Tools and resources
Information for the public
History

Appeal: UK Chronic Lymphocytic Leukaemia (CLL) Forum

Appeal received
Initial scrutiny letter
Response to initial scrutiny letter
Final scrutiny letter
Appraisal committee chair's response
Response to appraisal committee

This page was last updated: 21 May 2010